Investing.com -- Fitch Ratings has revised its outlook for biopharmaceutical company Amgen Inc (NASDAQ: AMGN ). to positive ...

Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. AMGN Stock Performance ...

The more we extend our horizon, the more likely it is that stocks will provide juicy returns. Investors can cash in by ...

this allowed it to broaden the pipeline beyond those molecules discovered in-house, much as the more traditional pharma companies were doing at this time. By the mid 2000s Amgen was already a giant.

Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical ...

Amgen’s discovery pipeline has led the company to broaden its focus from oncology, immunology, and renal disease to include musculoskeletal, cardiovascular, and neurologic conditions.

If Amgen can successfully bring these pipeline assets to market, it could offset potential losses from patent expirations and drive sustained long-term growth. This analysis is based on ...

With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...

Amgen and Kyowa Kirin have reported that the 24-week Phase III IGNITE trial assessing two dose strengths of rocatinlimab, in ...

In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...